Three Months Ended March 31, 2026

Common Shares

Paid-in Capital in Excess of Par Value

Accumulated Other Comprehensive Loss

Accumulated Deficit

Total Herbalife Shareholders’ Deficit

Noncontrolling Interests

Total Shareholders’ Deficit

(in millions)

Balance as of December 31, 2025

$

0.1

$

316.0

$

(251.5

)

$

(579.7

)

$

(515.1

)

$

5.7

$

(509.4

)

Issuance of 0.1 common shares from exercise of SARs, restricted stock units, employee stock purchase plan, and other

—

0.4

0.4

0.4

Additional capital from share-based compensation

10.6

10.6

10.6

Repurchases of less than 0.1 common shares

—

(0.7

)

—

(0.7

)

(0.7

)

Net income (loss)

61.9

61.9

(0.7

)

61.2

Foreign currency translation adjustment, net of income taxes of $(0.1)

(6.1

)

(6.1

)

(6.1

)

Unrealized loss on derivatives, net of income taxes of $—

(0.2

)

(0.2

)

(0.2

)

Other

—

7.7

7.7

2.3

10.0

Balance as of March 31, 2026

$

0.1

$

334.0

$

(257.8

)

$

(517.8

)

$

(441.5

)

$

7.3

$

(434.2

)

Three Months Ended March 31, 2025

Common Shares

Paid-in Capital in Excess of Par Value

Accumulated Other Comprehensive Loss

Accumulated Deficit

Total Shareholders’ Deficit

(in millions)

Balance as of December 31, 2024

$

0.1

$

278.2

$

(271.4

)

$

(808.0

)

$

(801.1

)

Issuance of 0.7 common shares from exercise of SARs, restricted stock units, employee stock purchase plan, and other

—

0.3

0.3

Additional capital from share-based compensation

11.6

11.6

Repurchases of 0.3 common shares

—

(2.2

)

—

(2.2

)

Net income

50.4

50.4

Foreign currency translation adjustment, net of income taxes of $0.4

8.7

8.7

Unrealized loss on derivatives, net of income taxes of $—

(3.7

)

(3.7

)

Balance as of March 31, 2025

$

0.1

$

287.9

$

(266.4

)

$

(757.6

)

$

(736.0

)